IMpower-131

IMpower-131

(PD1/PDL1-未)

Co-Primary Endpoint: OS(ITT), PFS(investigator)

Secondary Endpoint: PFS and OS in PD-L1 subgroups

Sq

化学療法未治療の非小細胞肺癌患者（1次治療）

・PD-L1発現 Any

R

Arm:B n=343

Atezolizumb(1200mg q3w) + CBDCA(AUC=6)+nab-PTX(100mg/m2) Up to 4-6 cycles → Maintenance Atezolizumb

※No Cross Over permitted

Arm:C n=340

CBDCA(AUC=5,6)+nab-PTX(200mg/m2) Up to 4-6 cycles → BSC

Arm:A n=338

Atezolizumb(1200mg q3w) + CBDCA(AUC=6)+PTX(200mg/m2)

	Primary	Subgroups		
investigator PFS	OS	PD-L1 High TC3 or IC3	PD-L1 Low TC1/2 or IC1/2	PD-L1 Negative TC0 or IC0
6.3ヵ月	14.0ヵ月	23.6ヵ月	12.4ヵ月	13.8ヵ月
HR=0.715 p=0.0001	HR=0.96 p=0.6931	HR=0.56	HR=1.34	HR=0.86
5.6ヵ月	13.9ヵ月	14.1ヵ月	16.6ヵ月	12.5ヵ月

2019/01/14

IMpower131: Study Design



Atezolizumab 1200 mg IV q3w; carboplatin AUC 6 IV q3w; nab-paclitaxel 100 mg/m² IV qw; paclitaxel 200 mg/m² IV q3w.
[a] Patients with a sensitising *EGFR* mutation or *ALK* translocation must have disease progression or intolerance to treatment with ≥ 1 approved targeted therapies. Testing for *EGFR* mutation or *ALK* translocation was not mandat
[b] PD-L1 expression was evaluated using the VENTANA SP142 IHC assay.

INV-Assessed PFS in the ITT Population (Arm B vs Arm C)

	Arm B: Atezo + CnP	Arm C: CnP
Median PFS (95% CI), mo	6.3 (5.7, 7.1)	5.6 (5.5, 5.7)
HR[a] (95% CI)	0.71 (0.60, 0.85)	
P value	0.0001	



Minimum follow-up, 9.8 mo
Median follow-up, 17.1 mo

No. at risk

Atezo + CnP	343	318	294	268	257	212	172	151	134	111	88	76	61	61	44	42	33	32	24	21	18	16	12	11	5	5	4	3	2	1
CnP	340	322	279	244	227	183	128	95	79	57	48	40	28	26	21	19	12	12	11	10	6	6	4	4	3	3	2	2	2	1

Data cutoff: January 22, 2018.
INV, investigator. [a] Stratified HR.

First Interim OS in the ITT Population (Arm B vs Arm C)



	Arm B: Atezo + CnP	Arm C: CnP
Median OS (95% CI), mo	14.0 (12.0, 17.0)	13.9 (12.3, 16.4)
HR[a] (95% CI) *P* value	0.96 (0.78, 1.18) 0.6931	

No. at risk

Atezo + CnP	343	319	306	298	290	279	269	256	239	220	203	177	150	137	118	103	95	81	73	63	51	42	34	32	23	16	12	5	3	2
CnP	340	324	311	295	285	271	255	236	224	213	196	167	142	120	103	94	76	66	53	43	32	30	21	17	14	11	6	4	3	2	1	1

Data cutoff: January 22, 2018.

[a] Stratified HR.

First Interim OS in PD-L1 Subgroups (Arm B vs Arm C)

PD-L1 High
TC3 or IC3



	Atezo + CnP	CnP
12-month OS	67%	52%
24-month OS	47%	30%
Median OS, mo	23.6	14.1
HR[a] (95% CI)	0.56 (0.32, 0.99)	

PD-L1 Low
TC1/2 or IC1/2



	Atezo + CnP	CnP
12-month OS	54%	64%
24-month OS	28%	37%
Median OS, mo	12.4	16.6
HR[a] (95% CI)	1.34 (0.95, 1.90)	

PD-L1 Negative
TC0 and IC0



	Atezo + CnP	CnP
12-month OS	53%	53%
24-month OS	30%	16%
Median OS, mo	13.8	12.5
HR[a] (95% CI)	0.86 (0.65, 1.15)	

Data cutoff: January 22, 2018.
[a] Unstratified HR.